Mesothelioma therapeutic agent

• US 20070134242A1
• Filed: 10/15/2004
• Published: 06/14/2007
• Est. Priority Date: 10/17/2003
• Status: Abandoned Application

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Kishimoto, Tadamitsu, Nishimoto, Norihiro, Takayama, Koichi, Adachi, Yasuo
• Application Number:
  US10/575,455
• Publication Number:
  US 20070134242A1
• Time in Patent Office: Days
• US Class Current: 424/145.100
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention provides a mesothelioma therapeutic agent containing an interleukin-6 (IL-6) antagonist such as antibody to IL-6 receptor (IL-6R), and a mesothelioma cell growth inhibitor containing an IL-6 antagonist such as antibody to IL-6R.

Claims

1. A mesothelioma therapeutic agent that contains an interleukin-6 (IL-6) antagonist as its active ingredient.

2. A mesothelioma therapeutic agent according to claim 1 wherein, the mesothelioma is pleural mesothelioma.

3. A mesothelioma therapeutic agent according to claim 2 wherein, the pleural mesothelioma is malignant pleural mesothelioma.

4. A mesothelioma therapeutic agent according to claim 1 wherein, the IL-6 antagonist is antibody to IL-6 receptor.

5. A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is monoclonal antibody to IL-6 receptor.

6. A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is monoclonal antibody to human IL-6 receptor.

7. A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is monoclonal antibody to mouse IL-6 receptor.

8. A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is recombinant antibody.

9. A mesothelioma therapeutic agent according to claim 6 wherein, the monoclonal antibody to human IL-6 receptor is PM-1 antibody.

10. A mesothelioma therapeutic agent according to claim 7 wherein, the monoclonal antibody to mouse IL-6 receptor is MR16-1 antibody.

11. A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is chimeric antibody, humanized antibody or human antibody.

12. A mesothelioma therapeutic agent according to claim 11 wherein, the humanized antibody to IL-6 receptor is humanized PM-1 antibody.

13. A growth inhibitor against mesothelioma cells that contains an interleukin-6 (IL-6) antagonist as its active ingredient.

14. A growth inhibitor according to claim 13 wherein, the mesothelioma is pleural mesothelioma.

15. A growth inhibitor according to claim 14 wherein, the pleural mesothelioma is malignant pleural mesothelioma.

16. A growth inhibitor according to claim 13 wherein, the IL-6 antagonist is antibody to IL-6 receptor.

17. A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is monoclonal antibody to IL-6 receptor.

18. A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is monoclonal antibody to human IL-6 receptor.

19. A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is monoclonal antibody to mouse IL-6 receptor.

20. A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is recombinant antibody.

21. A growth inhibitor according to claim 18 wherein, the monoclonal antibody to human IL-6 receptor is PM-1 antibody.

22. A growth inhibitor according to claim 19 wherein, the monoclonal antibody to mouse IL-6 receptor is MR16-1 antibody.

23. A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is chimeric antibody, humanized antibody or human antibody.

24. A growth inhibitor according to claim 23 wherein, the humanized antibody to IL-6 receptor is humanized PM-1 antibody.